902
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Cladribine in multiple sclerosis: pitfalls in a new treatment landscape

, MD
Pages 1-3 | Published online: 21 Dec 2012

Bibliography

  • Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-32
  • Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68:S22-31
  • Crespy L, Zaaraoui W, Lemaire M, Prevalence of grey matter pathology in early multiple sclerosis assessed by magnetization transfer ratio imaging. PLoS One 2011;6(9):e24969
  • Vogt J, Paul F, Aktas O, Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol 2009;66:310-22
  • Sinnecker T, Mittelstaedt P, Dorr J, Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study. Arch Neurol 2012;69:739-45
  • Sormani MP, Calabrese M, Signori A, Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studies. PLoS One 2011;6(10):e26712
  • Freedman MS. Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology 2011;76:S26-34
  • Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 2011;76:S14-25
  • Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology 2010;74:2004-15
  • Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551-4
  • O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50
  • Haghikia A, Perrech M, Pula B, Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS One 2011;6(4):e18506
  • Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012;78:672-80
  • Heesen C, Kleiter I, Nguyen F, Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler 2010;16:1507-12
  • Comi G, Hartung HP, Kurukulasuriya Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother 2013;14(1):123-36
  • Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
  • Giovannoni G, Comi G, Cook S, A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26
  • Cook S, Vermersch P, Comi G, Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRibine Tablets treating multiple sclerosis orallY) study. Mult Scler 2011;17:578-93
  • European Medicines Agency (EMA). Withdrawal assessment report for Movectro. 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2011/03/WC500104393.pdf
  • Shiee N, Bazin PL, Zackowski KM, Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS One 2012;7(5):e37049
  • Weinges-Evers N, Brandt AU, Bock M, Correlation of self-assessed fatigue and alertness in multiple sclerosis. Mult Scler 2010;16:1134-40
  • Hardmeier M, Schoonheim MM, Geurts JJ, Cognitive dysfunction in early multiple sclerosis: altered centrality derived from resting-state functional connectivity using magneto-encephalography. PLoS One 2012;7(7):e42087
  • Veauthier C, Radbruch H, Gaede G, Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. Mult Scler 2011;17:613-22
  • Ruet A, Deloire M, Hamel D, Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study. J Neurol 2012; [Epub ahead of print]
  • Bock M, Brandt AU, Dorr J, Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. Mult Scler 2010;16:893-6
  • Oberwahrenbrock T, Schippling S, Ringelstein M, Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int 2012;2012:530305

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.